Buy & Sell Affirm Holdings Inc (AFRM) – Affirm Holdings Inc Price Today
Aura AI Summary
Key Stats
- $22.04BMarket Cap
- FinancialsSector
- -18.99%3M Drawdown
- $28.65BEnterprise Value
- -Dividend Yield
- 21 daysTypical Hold Time
Affirm Holdings Inc (AFRM) is currently valued at a market capitalization of $22.04B, with an enterprise value of $28.65B. Over the past 52 weeks, Affirm Holdings Inc has traded between a low of $42.53 and a high of $92.18, highlighting its annual price range. Over the past three months, Affirm Holdings Inc has recorded a drawdown of -18.99%, reflecting recent price volatility. On average, investors hold Affirm Holdings Inc for approximately 21 days, indicating typical investor behavior on the platform.
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Most Recent News
Japanese partner urges caution on Tavneos use amid safety concerns and FDA scrutiny.
Kissei Pharmaceutical, Amgen's Japanese partner, has advised doctors to exercise caution when prescribing Tavneos (avacopan) due to safety concerns, including risks of liver dysfunction. This follows FDA warnings and a proposed withdrawal of Tavneos ...
Pepeto presale nears Binance listing, promising bigger returns than XRP's forecasted growth.
Pepeto is preparing for a Binance listing amid a forming crypto bull run, with its presale raising over $10 million and showing strong community growth. The project offers a zero-fee exchange with AI contract screening and cross-chain capabilities, a...
ImmunityBio gains exclusive U.S. rights to Tokyo-172 BCG for bladder cancer after positive Phase 3 trial.
ImmunityBio secured exclusive U.S. development and supply rights for the Tokyo-172 strain of BCG, an investigational bladder cancer therapy not yet FDA-approved. This follows positive Phase 3 trial results showing Tokyo-172 BCG is as effective as the...